More recently, Hasegawa et al. (19) noted the presence of SP-D in lung cancer, and demonstrated that SP-D was able to interfere, via its CRD region, with the interaction between EGF and EGF receptor (EGFR), a tyrosine kinase receptor of the ErbB family, causing downregulation of the EGF induced signaling (19). This evidence concerns the gene SFTPD and lung cancer.